Cohance Lifesciences Limited

Cohance Lifesciences Limited

Cohance Lifesciences Limited has informed the Exchange about a copy of newspaper publication regarding un-audited financial results for the quarter ended 30 June 2026.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has uploaded the audio recording of its conference call for the quarter ended 30 June 2026 on its website.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has informed the Exchange about the completion of a USFDA inspection of its manufacturing facility. The inspection was conducted from July 27, 2026, to August 5, 2026, and resulted in five observations, none of which relate to data integrity issues. The company is committed to addressing the observations and will submit a comprehensive response to the USFDA within the stipulated timeline.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has informed the Exchange about Investor Presentation, which includes unaudited financial results for Q1 FY2027. The company's revenue declined 23.1% YoY, and EBITDA declined 2.2% YoY. The management has acted on two immediate priorities—building an integrated nucleic-acid business and repositioning Agrochemicals towards a broader innovator-product-led portfolio. The company expects sequential improvement from Q2 and growth to return during H2 FY27.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations of ₹4,223 million, down 23.1% year-on-year, and adjusted EBITDA of ₹92 million. The company has guided for a strong growth rebound in the second half of the year, supported by secured orders, scheduled deliveries, and progress across its late-stage pipeline.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at ₹422.26 crore and net profit after tax at ₹8.31 crore.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has informed the Exchange about allotment of Equity Shares pursuant to exercise of Stock Options and grant of Stock Options to certain eligible employees of the Company.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has scheduled a conference call on August 5, 2026, at 6:30 pm IST to discuss its unaudited Q1 FY27 financial results, which will be announced earlier the same day.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has responded to the National Stock Exchange's clarification request regarding its financial results for the quarter ended 30-Sep-2025. The company has provided clarification on the filing of non-machine readable form of financial results and has submitted revised financial results in XBRL format on 17 July 2026.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized or rematerialized during the quarter ended June 30, 2026.

Cohance Lifesciences Limited

Jusmiral Holdings Limited, the promoter of Cohance Lifesciences Limited, has submitted a disclosure under SEBI Takeover Regulations stating that they have not made any encumbrance on the company's shares, directly or indirectly, other than those already disclosed during the financial year 2025-26.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has informed the Exchange about a copy of newspaper publication regarding the company's intention to submit an application seeking approval of the Central Government with respect to the appointment of Mr. Umang Vohra as a non-resident director.

Cohance Lifesciences Limited

Cohance Lifesciences Limited's promoter, Berhyanda Limited, along with persons acting in concert, submitted a disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. They declared that no new encumbrances (pledges) have been created on the company's shares, either directly or indirectly, during the financial year 2025-26. This announcement reassures that only previously disclosed encumbrances exist, indicating stability in the promoter's shareholding pledge status.

Cohance Lifesciences Limited

Cohance Lifesciences Limited has informed the Exchange about the resignation of a Director/KMP/SMP.